Dulamet 200 HFA

Indications

Prescribed for asthma symptoms control and prevention, particularly in patients aged 12 and above. Contains Formoterol, a Long Acting β2 Agonist (LABA), alongside an Inhaled Corticosteroid (ICS), minimizing the risk of hospitalizations and death associated with asthma exacerbations. Recommended for patients requiring both ICS and LABA treatment.

Composition:

Available in 100 HFA and 200 HFA inhaler variants, delivering Mometasone Furoate and Formoterol Fumarate Dihydrate in specified microgram doses.

Pharmacology

Mometasone furoate, an ICS, reduces lung inflammation, while Formoterol fumarate, a LABA, relaxes muscles around the airways, preventing asthma symptoms.

Dosage

Adults and adolescents aged 12 and older typically administer 2 inhalations twice daily, with dosage strengths dependent on disease severity.

Administration

Shake inhaler, exhale gently, and inhale deeply through the mouth while pressing the canister to release the powder. Hold breath for 10 seconds post-inhalation, then exhale slowly. Clean mouthpiece regularly to prevent powder buildup.

Interaction

Use with caution alongside certain inhibitors, adrenergic agents, xanthine derivatives, diuretics, and other medications affecting the cardiovascular system.

Contraindications

Not suitable for primary treatment of acute asthma episodes or patients with known hypersensitivity to its ingredients.

Side Effects

Common side effects include inflammation of the nose and throat, headache, and flu-like symptoms, while less common effects may include allergic reactions and reduced adrenal function.

Pregnancy & Lactation

Limited data available; benefits must outweigh risks for use during pregnancy and lactation.

Use in Special Populations

No specific data for hepatic/renal impairment; caution advised. Pharmacokinetics in elderly populations not studied.

Storage Conditions

Store below 30°C, away from sunlight, and keep out of children’s reach. Avoid puncturing or breaking the container.